KIT^D816V Induces SRC-Mediated Tyrosine Phosphorylation of MITF and Altered Transcription Program in Melanoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The KIT^D816V mutation is linked to systemic mastocytosis and acute myeloid leukemia.
• The role and function of KIT^D816V in melanoma remain unclear.
• Understanding KIT^D816V's oncogenic mechanisms in melanoma is crucial for targeted therapies.

Purpose of the Study:

• To elucidate the molecular mechanism by which KIT^D816V contributes to melanoma.
• To investigate the interaction between KIT^D816V, MITF, and SRC family kinases in melanoma cells.
• To identify potential therapeutic strategies targeting the KIT^D816V pathway in melanoma.

Main Methods:

• Protein complex formation analysis.
• Tyrosine phosphorylation assays.
• Gene expression profiling of MITF target genes.
• Assessment of cellular phenotypes including proliferation, senescence, survival, and invasion.
• Evaluation of drug sensitivity to SRC inhibitors.

Main Results:

• KIT^D816V forms a triple protein complex with MITF and SRC family kinases.
• This complex induces tyrosine phosphorylation of MITF.
• Phosphorylated MITF activates genes promoting melanoma proliferation, cell-cycle progression, senescence suppression, survival, and invasion.
• Inhibition of the triple complex formation sensitizes melanoma cells to SRC inhibitors.

Conclusions:

• KIT^D816V oncogenic effects in melanoma are mediated by MITF phosphorylation.
• The KIT^D816V-MITF-SRC complex is a key driver of melanoma progression.
• Targeting this complex offers a therapeutic rationale for enhanced SRC inhibitor efficacy in KIT^D816V-mutated melanoma.